Press release & events

We'll be there! Meet Explicyte at AACR event in New Orleans

03 / 29 / 2022

We'll be there! Meet Explicyte at AACR event in New Orleans

We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there,  approach your research projects and introduce our service offerings. We will also presentsome scientific posters to highlight our latest innovative preclinical and translational research advances.

Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology

03 / 10 / 2022

Domain Therapeutics and Explicyte enter  partnership agreement in immuno-oncology

Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement. The two companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic programs for IO. Financial terms are not disclosed.

CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10M in the fifth RHU call

01 / 27 / 2022

CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10M in the fifth RHU call

January 27, 2022 – The CONDOR consortium, led by Pr. Antoine Italiano of the Bergonié Institute (Bordeaux, France) is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5), selected from the 89 applications submitted. This €30M ($34M) project will benefit from a grant of more than €9.8M ($11.1M) to implement a multi-modal project combining precision medicine and immunotherapies for the management of patients with Soft Tissue Sarcomas (STS).

Explicyte is CIR approved!

10 / 28 / 2019

We are proud to announce that the French Ministry for Higher Education and Research has recognised Explicyte / Immusmol SAS as a "Credit Import Recherche" (CIR) approved research and development service provider.